Psoriasis Flashcards

1
Q

Epidemiology of psoriasis

A

2% of population

Equal sex incidence

2nd-3rd and 6th decade (bimodal peak incidence)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Aetiology of psoriasis

A

Hyperproliferation of keratinocytes and inflammatory cell infiltration

Ppt by trauma (Kobner), infection (esp strep throat), drugs, stress, alcohol

UV light helps but not always (lowest incidence equator)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Types of psoriasis

A

Chronic plaque

Guttate - post-streptococcal

Seborrheic

Flexural

Pustular

Erythrodermic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Features of psoriasis plaques

A

Silvery, rough scale

Clearly demarcated

Erythematous background

Can be itchy, burning, painful

Auspitz sign - pinpoint bleeding when they’re touched

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Nail changes in psoriasis

A

Affects 50%

Onycholysis

Pitting

Subungual hyperkeratosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Koebner phenomenon

A

Rash ‘colonises’ site of recent trauma (e.g. excoriation) - line marking

Esp tattoos

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Distribution of psoriasis

A

Extensor surfaces

Scalp

Palmo-plantar

Retro-auricular

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Auspitz sign

A

Removal of psoriasis scale results in pinpoint capillary bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Drugs exacerbating psoriasis

A

Antimalarials

Beta blockers

Lithium

Acute steroid withdrawal

Rampant psoriasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Complications of psoriasis

A

Erythroderma

Social phobia, depression

Vit D deficiency, deconditioning

Skin atrophy from prolonged potent topical steroids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Differential between seb derm and seb psoriasis

A

Psoriasis more sharply demarcated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Differential between psoriasis and eczema

A

Eczema more itchy

Less well demarcated

Flexor > extensor

Less erythematous

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Clinical course based on early vs late onset

A

Early onset - 16-22

Irregular course, more severe, increased psych comorbidity, tendency to become generalised

Late onset - 57-62

Milder, more localised

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Pathogenesis of psoriasis

A

T-cell driven

Th1: TNF-a, IL-2, IFN-g

Th17: IL-17 for neutrophils, IL-23 for keratinocyte proliferation and keratosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q
A

Chronic plaque psoriasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Management of psoriasis - patient education

A

Control not cure

Avoid known triggers

Emollients to reduce scale (esp for scalp)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Topical treatments for psoriasis

A

Localised, mild disease

Vit D analogues

Coal tar preparations

Topical retinoids/VitA analogues

Topical steroid

Anti-yeast (seborrheic)

alongside emollient

Most topicals may cause irritation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q
A

Inverse psoriasis

Friction > loss of scale > shiny plaque or fissure

19
Q
A

Guttate psoriasis

Associated with infection (Esp strep throat) in adolescence

Raindrop, ‘spotty’ lesions

20
Q
A

Palmo-plantar pustular psoriasis

Collection of neutrophils

Can result from inappropriate sue of oral steroids

If generalised > skin failure

21
Q

Assessment of psoriasis severity

A

PASI

Looking at thickness, erythema, coverage, scale

In: head + neck, trunk, upper limb, lower limb

22
Q

Patterns of psoriatic arthritis

A

Distal interphalangeal joint

Dactylitis

Arthritis mutilans (DIP flexion deformities, digit shortening)

Symmetrical polyarthritis (RA-like)

Spondyloarthritis

Asymmetrical oligoarthritis

23
Q

Comorbidities with psoriasis

A

Psychiatric - depression/anxiety

Metabolic syndrome and CVD - from inflammation

Smoking/alcohol - cause and effect? worsen illness

24
Q

Name of vitamin d analogue

A

Calcipotriol

May cause hypercalcaemia with prolonged use

25
Name of coal tar analogue
exorex will stain bedsheets! Advise patient
26
Management of scalp psoriasis
Coal tar based treatment/emollient overnight to descale Steroid for inflammation Anti-yeast
27
Forms of psoriasis phototherapy
Narrow band UVB Psoralen-PUVA (can be hand/feet only)
28
Narrow band UVB therapy
311-312nm - most effective w/ least cancer risk 3x per week for 8 weeks
29
UVA therapy
Psoralen taken prior to therapy (topical if hands/feet) Psoralen absorbs UVA light - sensitises skin Then twice weekly Caution if prev immunosuppression
30
Systemic management of psoriasis
Methotrexate Acitretin Ciclosporin Fumaric acid esterase, mycophenolate mofetil less common
31
Methotrexate monitoring
Teratogenic - not pregnancy (but can be given to females) Limit EtOH Hepatitis, myelosuppression risk - FBC, LFTs, U&Es Folate supplementation
32
Methotrexate side effects
Nausea + vomiting Oral ulcers Myelosuppression, hepatitis Teratogenic - encourage contraception until 6mo after stopping Caution if suspecting infection to acute myelosuppression
33
Methotrexate dosing
10-25mg Once-weekly
34
Acitretin side effects
Vit A derivative (retinoid) Mucocutaeneous dryness Mood disturbance LFT and lipid profile monitoring Teratogenic - **contraception 1mo before and 3 years after stopping**
35
Ciclosporin side effects
Renal impairment Increased blood pressure Short-term treatment only
36
Acitretin dose
25mg daily
37
Ciclosporin ose
2.5-5mg/kg daily in two divided doses
38
NICE eligibility criteria for biologics
DLQI \>10 PASI \>10 Failed systemic treatment + phototherapy
39
Biologic targets
TNF-a IL-17 IL-12/23
40
TNF-a biologics
Adalimumab Etanercept Infliximab
41
IL-17 biologics
Secukinumab Brodalumab (receptor antagonist)
42
IL-12/23 biologics
Ustekinumab Inhibits p40 subunit
43
Differential for nail pitting
Eczema Lichen planus Psoriasis